Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
暂无分享,去创建一个
N. Sebire | Chris Jones | R. A’Hern | Richard Williams | A. Kelsey | K. Pritchard-Jones | B. Messahel | G. Vujanić | Reem Al-Saadi | M. Brundler | R. Hobson | A. Ridolfi | W. Warren | L. Tinworth | G. Whyman | Chris Jones
[1] P. Grundy,et al. Identification of a minimal region of loss on the short arm of chromosome 1 in Wilms tumor , 2007, Genes, chromosomes & cancer.
[2] M. Gessler,et al. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis , 2007, Genes, chromosomes & cancer.
[3] D. Machin,et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. , 2006, European journal of cancer.
[4] K Fenwick,et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse , 2006, The Journal of pathology.
[5] N. Breslow,et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Colella,et al. Genome‐wide loss of heterozygosity analysis of WT1–wild‐type and WT1‐mutant Wilms tumors , 2005, Genes, chromosomes & cancer.
[7] P. Voûte,et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] D. Green,et al. The treatment of stages I-IV favorable histology Wilms' tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Kelsey,et al. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Bentley,et al. Fine Mapping of Wilms’ Tumors With 16q Loss of Heterozygosity Localizes the Putative Tumor Suppressor Gene to a Region of 6.7 Megabases , 2003, Annals of Surgical Oncology.
[11] I. Tomlinson,et al. Loss of heterozygosity analysis: Practically and conceptually flawed? , 2002, Genes, chromosomes & cancer.
[12] Dieter Harms,et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. , 2002, Medical and pediatric oncology.
[13] M. Gessler,et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. , 2001, The American journal of pathology.
[14] A. Kelsey,et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study , 2000, British Journal of Cancer.
[15] S. Avigad,et al. High frequency of loss of heterozygosity for 1p35-p36 (D1S247) in Wilms tumor. , 2000, Cancer genetics and cytogenetics.
[16] P. Scambler,et al. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. , 1998, British Journal of Cancer.
[17] M. Gessler,et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters , 1998, Genes, chromosomes & cancer.
[18] H. B. Marsden,et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] N. Breslow,et al. Loss of Heterozygosity for Chromosomes 16q and Ip in Wilms' Tumors Predicts an Adverse Outcome' , 2022 .
[20] N. Hastie,et al. The genetics of Wilms' tumor--a case of disrupted development. , 1994, Annual review of genetics.
[21] C. Heyting,et al. Chromosome 11 Putative Tumor Suppressor Regions , Is Limited to Loss of Heterozygosity in Wilms ' Tumors , Studied for Six Updated , 2006 .